Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS 15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 16	FEB 22	Status of current WO (PCT) information on STN
NEWS 17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 18	FEB 22	Updates in EPFULL; IPC 8 enhancements added

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 14:13:19 ON 23 FEB 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:13:27 ON 23 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 FEB 2006  HIGHEST RN 874945-83-2
DICTIONARY FILE UPDATES:  22 FEB 2006  HIGHEST RN 874945-83-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10516500a.str
```





chain nodes :
11 12 17 18 19 20 21 22 23 24 26 28 29 30 31 32 33 34 35 36 37
38 39 40 41 42
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 25
chain bonds :
1-19 1-24 2-20 2-42 3-30 3-31 4-28 4-29 6-22 7-11 7-21 8-18 9-34 9-35
10-32 10-33 11-12 11-40 11-41 12-25 12-39 13-26 13-38 14-36 14-37 16-17
19-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-25 14-15 15-16
16-25
exact/norm bonds :
2-20 13-14 13-25 13-26 14-15 15-16 16-25 16-17
exact bonds :
1-2 1-6 1-19 1-24 2-3 2-42 3-4 3-30 3-31 4-5 4-28 4-29 5-6 5-7 6-10
6-22 7-8 7-11 7-21 8-9 8-18 9-10 9-34 9-35 10-32 10-33 11-12 11-40
11-41 12-25 12-39 13-38 14-36 14-37 19-23
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:13:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       13 TO ITERATE

100.0% PROCESSED       13 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           44 TO      476
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:14:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      196 TO ITERATE

100.0% PROCESSED      196 ITERATIONS                                13 ANSWERS
SEARCH TIME: 00.00.01

L3           13 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 14:14:07 ON 23 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2006 VOL 144 ISS 9
FILE LAST UPDATED: 22 Feb 2006 (20060222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 267 L3

=> s l4 and pharm?
554325 PHARM?
L5 63 L4 AND PHARM?

=> s l4 and py<2004
23835580 PY<2004
L6 194 L4 AND PY<2004

=> s l6 and pharm?
554325 PHARM?
L7 41 L6 AND PHARM?

=> uspatfull
USPATFULL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.23	174.38

FILE 'USPATFULL' ENTERED AT 14:16:11 ON 23 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 21 Feb 2006 (20060221/PD)
FILE LAST UPDATED: 21 Feb 2006 (20060221/ED)
HIGHEST GRANTED PATENT NUMBER: US7003800
HIGHEST APPLICATION PUBLICATION NUMBER: US2006037120
CA INDEXING IS CURRENT THROUGH 21 Feb 2006 (20060221/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 21 Feb 2006 (20060221/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=> s l3 full
L8 29 L3

=> s l8 and py<2004
3680210 PY<2004
L9 15 L8 AND PY<2004

=> d ibib abs hitstr 1-15

L9 ANSWER 1 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2003:293965 USPATFULL
TITLE: Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
INVENTOR(S): Sherwood, Bob, Amenia, NY, UNITED STATES
Zeleznik, Joseph A., Poughkeepsle, NY, UNITED STATES
Schaible, David, Ulster Park, NY, UNITED STATES
Berkulin, Wilhelm, Alsbach, GERMANY, FEDERAL REPUBLIC OF
Theissing, Karl-Hans, Alzenau-Horstein, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003206978	A1	20031106	<--
APPLICATION INFO.:	US 2002-256826	A1	20020927	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-334430P	20011130 (60)
	US 2001-334399P	20011129 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018
NUMBER OF CLAIMS: 189
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2189
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In certain preferred embodiments, step b comprises combining said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer. Preferably, the dryer is a spray dryer, and, in certain embodiments, the active agent may be an herbal extract.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **5508-58-7**, Andrographolide
(agglomerated particles containing processed with silicified microcryst. cellulose)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 2 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2003:282316 USPATFULL
TITLE:	Methods using phytol to improve the appearance of skin and compositions for such methods
INVENTOR(S):	Menon, Gopinathan K., Wayne, NJ, UNITED STATES Ptchelintsev, Dmitri, Jersey City, NJ, UNITED STATES Mahalingam, Harish, Ledgewood, NJ, UNITED STATES
PATENT ASSIGNEE(S):	Avon Products, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003198657	A1	20031023	<--
APPLICATION INFO.:	US 2003-442219	A1	20030520 (10)	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-724356, filed on 28 Nov 2000, ABANDONED			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190988P	20000321 (60)
	US 2000-190989P	20000321 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	CHARLES N.J. RUGGIERO, ESQ., OHLANDT, GREELEY, RUGGIERO & PERLE, L.L.P., 10th FLOOR, ONE LANDMARK SQUARE, STAMFORD, CT, 06901-2682
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
LINE COUNT:	437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided methods of enhancing the appearance of human skin comprising applying a composition having (i) phytol in an amount about 0.0001 wt % to about 50 wt % based on the total weight of the composition, and (ii) at least one retinoid in an amount about 0.001 wt % to about 1.5 wt % based on the total weight of the composition. Alternatively, the composition used in the method for enhancing the appearance of human skin may have phytol and perilla oil.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(skin care compns. containing phytol and other cell signaling compds. that mediate cell to cell communication)

RN 5508-58-7 USPATFULL

CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-

(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 3 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2003:159015 USPATFULL			
TITLE:	Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2			
INVENTOR(S):	Babish, John G., Brooktondale, CA, UNITED STATES Howell, Terrence, Dryden, NY, UNITED STATES Pacioretty, Linda, Brooktondal, NY, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003108628	A1	20030612	<--
	US 6979470	B2	20051227	
APPLICATION INFO.:	US 2002-198277	A1	20020716	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-306055P		20010717	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	M. Wayne Western, THORPE, NORTH & WESTERN, L.L.P., P.O. Box 1219, Sandy, UT, 84091-1219			
NUMBER OF CLAIMS:	20			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Page(s)			
LINE COUNT:	1410			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(curcuminoid compns. exhibiting synergistic inhibition of the

expression and/or activity of cyclooxygenase-2)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 4 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2003:140187 USPATFULL
TITLE: Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
INVENTOR(S): Babish, John G., Brooktondale, NY, UNITED STATES
Howell, Terrence M., Freeville, NY, UNITED STATES
Pacioretty, Linda M., Brooktondale, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096027	A1	20030522	<--
APPLICATION INFO.:	US 2002-282236	A1	20021025	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335062P	20011026 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1186
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **5508-58-7**, Andrographolide
(synergistic inhibition of cyclooxygenase-2 by curcuminoid combinations with α- or β-acids from hops for treatment of inflammation)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2003:50863 USPATFULL
TITLE:	Skin care composition that mediates cell to cell communication
INVENTOR(S):	Anderson, Glen T., Cortlandt Manor, NY, UNITED STATES Ptchelintsev, Dmitri S., Jersey City, NJ, UNITED STATES Menon, Gopinathan K., Wayne, NJ, UNITED STATES Duffy, John A., West Milford, NJ, UNITED STATES
PATENT ASSIGNEE(S):	Avon Products, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003035819	A1	20030220	<--
APPLICATION INFO.:	US 2002-198772	A1	20020719 (10)	

RELATED APPLN. INFO.: Division of Ser. No. US 2001-812707, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 1999-461449, filed on 14 Dec 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US33776	20001214
	US 2000-190988P	20000321 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	CHARLES N.J. RUGGIERO, ESQ., OHLANDT, GREELEY, RUGGIERO & PERLE, L.L.P., 10th FLOOR, ONE LANDMARK SQUARE, STAMFORD, CT, 06901-2682
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
LINE COUNT:	700

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed skin treatment compositions containing cell signaling compounds, which induce and promote the biosynthesis and/or bioactivity of endogenous chemicals that mediate cell to cell communication in the skin between keratinocytes, fibroblasts and other cell types present in the skin. The cell signaling compound is selected from the group consisting of: andrographolide and its derivatives; adenosine cyclic phosphate and its derivatives; hydrolyzed milk proteins; sunflower seed extract; plankton extract; phytol and its derivatives; and mixtures thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(skin care compns. containing phytol and other cell signaling compds. that mediate cell to cell communication)

RN 5508-58-7 USPATFULL

CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:301217 USPATFULL

TITLE: Peptidomimetic modulators of cell adhesion

INVENTOR(S): Gour, Barbara J., Kemptville, CANADA
Blaschuk, Orest W., Westmount, CANADA
Ali, Anmar, Ottawa, CANADA
Ni, Feng, Pierrefonds, CANADA
Chen, Zhigang, Pierrefonds, CANADA
Michaud, Stephanie D., Ottawa, CANADA
Wang, Shoameng, Saline, MI, UNITED STATES
Hu, Zenjian, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002168761	A1	20021114	<--
APPLICATION INFO.:	US 2001-769145	A1	20010124 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-491078, filed on 24 Jan 2000, PENDING

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 183
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 201 Drawing Page(s)
LINE COUNT: 5685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **5508-58-7**, 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 7 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:149194 USPATFULL
TITLE: Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2
INVENTOR(S): Babish, John G., Brooktondale, NY, UNITED STATES
Howell, Terrence, Dryden, NY, UNITED STATES
Pacioretty, Linda, Brooktondale, NY, UNITED STATES
PATENT ASSIGNEE(S): Ashni Naturaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002077350	A1	20020620	<--
APPLICATION INFO.:	US 2001-919510	A1	20010731 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-222190P	20000801 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THORPE NORTH WESTERN, 8180 SOUTH 700 EAST, SUITE 200, P.O. BOX 1219, SANDY, UT, 84070
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component, a diterpene triepoxide lactone species or a sesquiterpene lactone species and, as a second component, at least one member selected from the group consisting of a diterpene triepoxide lactone species, a sesquiterpene lactone species, a diterpene lactone species, and a triterpene species or derivatives thereof with the proviso that the same first component cannot also serve as the second component., and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide **120850-17-1**
(terpene compound compns. having synergistic cyclooxygenase 2 inhibition, and use as antiinflammatory agents)

RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 120850-17-1 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, didehydro deriv., (3E,4S)- (9CI) (CA INDEX NAME)

CM 1

CRN 5508-58-7
CMF C20 H30 O5

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2002:133248 USPATFULL			
TITLE:	Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2			
INVENTOR(S):	Babish, John G., Brooktondale, NY, UNITED STATES Howell, Terrence, Dryden, NY, UNITED STATES Pacioretty, Linda, Brooktondale, NY, UNITED STATES			
PATENT ASSIGNEE(S):	Ashni Naturaceuticals, Inc. (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002068098	A1	20020606	<--
	US 6629835	B2	20031007	
APPLICATION INFO.:	US 2001-920339	A1	20010801	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-222166P		20000801	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	THORPE NORTH WESTERN, 8180 SOUTH 700 EAST, SUITE 200, P.O. BOX 1219, SANDY, UT, 84070			
NUMBER OF CLAIMS:	58			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	7 Drawing Page(s)			
LINE COUNT:	1571			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component selected from the group consisting of a diterpene lactone species and a triterpene species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(combinations of diterpene triepoxide lactones and diterpene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 9 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2002:55066 USPATFULL			
TITLE:	Novel compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them			
INVENTOR(S):	Nanduri, Srinivas, Hyderabad, INDIA Rajagopal, Sriram, Hyderabad, INDIA Pothukuchi, Sairam, Hyderabad, INDIA Pillai, Sunilkumar Bhadramma Kochunarayana, Hyderabad, INDIA Chakrabarti, Ranjan, Hyderabad, INDIA			
PATENT ASSIGNEE(S):	DR. REDDY'S RESEARCH FOUNDATION (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002032229	A1	20020314	<--
	US 6410590	B2	20020625	
APPLICATION INFO.:	US 2001-775533	A1	20010201	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	IN 2000-892000		20000203	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61 Street, New York, NY, 10023			
NUMBER OF CLAIMS:	27			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1439			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel derivatives of Andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel

derivatives of Andrographolide have the general formula (I) ##STR1##

The andrographolide derivatives represented by general formula (I) are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis, other cardiovascular disorders, and can be used as antiviral, antimalarial, antibacterial, hepatoprotective, and immunomodulating agents and for treatment of other metabolic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **5508-58-7**, Andrographolide
(preparation and antitumor activity of andrographolide derivs.)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 10 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:27515 USPATFULL
TITLE: Novel anticancer compounds : process for their preparation and pharmaceutical compositions containing them
INVENTOR(S): Nanduri, Srinivas, Hyderabad, INDIA
Pothukuchi, Sairam, Hyderabad, INDIA
Rajagopal, Sriram, Hyderabad, INDIA
Akella, Venkateswarlu, Hyderabad, INDIA
Pillai, Sunilkumar Bhadramma Kochunarayana, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
PATENT ASSIGNEE(S): DR. REDDY'S RESEARCH FOUNDATION (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002016363	A1	20020207	<--
	US 6486196	B2	20021126	
APPLICATION INFO.:	US 2001-849586	A1	20010504	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2000-3542000	20000505

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ladas & Parry, 26 West 61 Street, New York, NY, 10023
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 2168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **5508-58-7**, Andrographolide
(preparation of andrographolide derivs. and pharmaceutical compns. containing
them for use as novel anticancer agents)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 11 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2002:27476 USPATFULL
TITLE: Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them
INVENTOR(S): Nanduri, Srinivas, Andhra Pradesh, INDIA
Rajagopal, Sriram, Andhra Pradesh, INDIA
Akella, Venkateswarlu, Andhra Pradesh, INDIA
PATENT ASSIGNEE(S): DR. REDDY'S RESEARCH FOUNDATION (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002016324	A1	20020207	<--
	US 6576662	B2	20030610	
APPLICATION INFO.:	US 2001-849584	A1	20010504 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2000-3532000	20000505
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ladas & Parry, 26 West 61 Street, New York, NY, 10023	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2950	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**
(preparation of andrographolide derivs. for pharmaceutical use in the treatment of a variety of diseases, such as cancer and HIV infection)

RN 5508-58-7 USPATFULL

CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 12 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2002:12007 USPATFULL
TITLE:	Skin care composition that mediates cell to cell communication
INVENTOR(S):	Anderson, Glen T., Manor, NY, UNITED STATES Ptchelintsev, Dmitri S., Jersey City, NJ, UNITED STATES Menon, Gopinathan K., Wayne, NJ, UNITED STATES Duffy, John A., West Milford, NJ, UNITED STATES
PATENT ASSIGNEE(S):	Avon Products, Inc., New York, NY, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002006383	A1	20020117	<--
APPLICATION INFO.:	US 2001-812707	A1	20010320 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-461449, filed on 14 Dec 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US33776	20001214
	US 2000-190988P	20000321 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Charles N.J. Ruggiero, Esq., Ohlandt, Greeley, Ruggiero & Perle, L.L.P., One Landmark Square, 10th Floor, Stamford, CT, 06901-2682
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed skin treatment compositions containing cell signaling compounds, which induce and promote the biosynthesis and/or bioactivity of endogenous chemicals that mediate cell to cell communication in the skin between keratinocytes, fibroblasts and other cell types present in the skin. The cell signaling compound is selected from the group consisting of: andrographolide and its derivatives; adenosine cyclic phosphate and its derivatives; hydrolyzed milk proteins; sunflower seed extract; plankton extract; phytol and its derivatives; and mixtures thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **5508-58-7**, Andrographolide
(skin care composition that mediates cell to cell communication)
RN 5508-58-7 USPATFULL
CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 13 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2000:146109 USPATFULL

TITLE: In vitro screening assay for identification of compounds that inhibit cytopathicity of viral infection

INVENTOR(S): Wheelock, Geoffrey D., Ithaca, NY, United States
Rininger, Joseph, Ithaca, NY, United States
Babish, John G., Ithaca, NY, United States
Chigurupati, Padmasree, Ithaca, NY, United States
PATENT ASSIGNEE(S): Paracelsian, Inc., Ithaca, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6140063		20001031	<--
APPLICATION INFO.:	US 1998-294442		19980813 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1997-780742, filed on 8 Jan 1997, now patented, Pat. No. US 5833994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Brown, Pinnisi & Michaels, PC
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1655

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur. The use of secondary compounds for use in combinational, synergistic, therapy is also enclosed. These second compounds are also known to have some effect on the treatment of cellular pathologic changes, together with those compounds found to be effective upon the regulation of the Ah receptor the compounds can more beneficially control virally induced cellular cytopathic changes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(aryl hydrocarbon (Ah) receptor and Ah receptor ligands and other compds. to treat or prevent cytopathicity of viral infection)

RN 5508-58-7 USPATFULL

CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER:	1999:33977 USPATFULL		
TITLE:	Potentiators of antibacterial agents		
INVENTOR(S):	Boggs, Amy, Menlo Park, CA, United States Trias, Joaquim, San Mateo, CA, United States Hecker, Scott, Los Gatos, CA, United States		
PATENT ASSIGNEE(S):	Microcide Pharmaceuticals, Inc., Mountainview, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5883074		19990316 <--
APPLICATION INFO.:	US 1995-388109		19950208 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Russel, Jeffrey E.		
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	1946		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for screening for compounds which potentiate the activity of antibacterial agents against bacteria resistant to the antibacterial agent alone, pharmaceutical compositions including such potentiators, and methods of treating bacterial infections using a combination of a potentiator and a potentiated antibacterial agent, which are useful for overcoming the resistance of a bacterial strain for an antibacterial agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(potentiators of antibacterial agents useful for overcoming resistance of bacterial strain for antibacterial agent alone, and screening methods)

RN 5508-58-7 USPATFULL

CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER:	1998:138446 USPATFULL
TITLE:	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
INVENTOR(S):	Wheelock, Geoffrey D., Ithaca, NY, United States Rininger, Joseph, Ithaca, NY, United States Babish, John G., Ithaca, NY, United States Chigurupati, Padmasree, Ithaca, NY, United States
PATENT ASSIGNEE(S):	Paracelsian, Inc., Ithaca, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5833994		19981110	<--
APPLICATION INFO.:	US 1997-780742		19970108	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Stucker, Jeffrey
LEGAL REPRESENTATIVE:	Brown, Pinnisi & Michaels, PC
NUMBER OF CLAIMS:	31
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur. The use of secondary compounds for use in combinational, synergistic, therapy is also enclosed. These second compounds are also known to have some effect on the treatment of cellular pathologic changes, together with those compounds found to be effective upon the regulation of the Ah receptor the compounds can more

beneficially control virally induced cellular cytopathic changes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **5508-58-7**, Andrographolide
(aryl hydrocarbon (Ah) receptor and Ah receptor ligands and other compds. to treat or prevent cytopathicity of viral infection)

RN 5508-58-7 USPATFULL

CN 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 14:13:19 ON 23 FEB 2006)

FILE 'REGISTRY' ENTERED AT 14:13:27 ON 23 FEB 2006
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 13 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:14:07 ON 23 FEB 2006
L4 267 S L3 FULL
L5 63 S L4 AND PHARM?
L6 194 S L4 AND PY<2004
L7 41 S L6 AND PHARM?

FILE 'USPATFULL' ENTERED AT 14:16:11 ON 23 FEB 2006
L8 29 S L3 FULL
L9 15 S L8 AND PY<2004

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	94.64	269.02

Connection closed by remote host